Page last updated: 2024-11-11

ci 1020

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9870830
CHEMBL ID8981
SCHEMBL ID4178950
MeSH IDM0246155

Synonyms (24)

Synonym
3-benzo[1,3]dioxol-5-yl-5-hydroxy-5-(4-methoxy-phenyl)-4-(3,4,5-trimethoxy-benzyl)-5h-furan-2-one
3-(benzo[d][1,3]dioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)furan-2(5h)-one
bdbm50034267
ci 1020
CHEMBL8981 ,
FT-0665027
3-(1,3-benzodioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]-2(5h)-furanone
162256-50-0
SCHEMBL4178950
3-benzo[1,3] dioxol-5-yl-5-hydroxy-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxy-benzyl)-5h-furan-2-one
PWIPORDFWDZCJG-UHFFFAOYSA-N ,
3-benzo[1,3]dioxol-5-yl-5-hydroxy-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxy-benzyl)-5h-furan-2-one
3-benzo[1,3]-dioxol-5-yl-5-hydroxy-5-(4-methoxy-phenyl)-4-(3,4,5-trimethoxy-benzyl)-5h-furan-2-one
AKOS024457348
DTXSID30432113
J-009914
3-(1,3-benzodioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-2(5h)-furanone
ci1020
2(5h)-furanone, 3-(1,3-benzodioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]-
3-(1,3-benzodioxol-5-yl)-5-hydroxy-5-(4-methoxyphenyl)-4-[(3,4,5-trimethoxyphenyl)methyl]furan-2-one
ci1020-d9
ci-1020
HY-103459
CS-0027936

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The compound has 70% oral bioavailability in rats."( 2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
Bal, R; Boyd, SA; Chiou, WJ; Dixon, DB; Hernandez, L; Jae, HS; Kester, JA; Mantei, RA; Marsh, KC; Novosad, EI; Opgenorth, TJ; Sorensen, BK; Tasker, AS; von Geldern, TW; Winn, M; Wu-Wong, JR, 1996
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Endothelin receptor type BHomo sapiens (human)IC50 (µMol)0.49200.00010.65659.8000AID66367; AID66520; AID66529; AID66545; AID66709
Endothelin receptor type BHomo sapiens (human)Ki0.13900.00010.05430.3710AID66691
Endothelin-1 receptorHomo sapiens (human)IC50 (µMol)0.00060.00000.76479.9000AID66034; AID68301; AID68315; AID68338
Endothelin-1 receptorHomo sapiens (human)Ki0.00020.00000.430010.0000AID68488
Endothelin-1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00040.00001.774610.0000AID66202
Endothelin receptor type BMus musculus (house mouse)IC50 (µMol)0.78000.78000.78000.7800AID452800
Endothelin-1 receptorMus musculus (house mouse)IC50 (µMol)0.00030.00030.00030.0003AID452799
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (109)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIEndothelin receptor type BHomo sapiens (human)
neural crest cell migrationEndothelin receptor type BHomo sapiens (human)
positive regulation of protein phosphorylationEndothelin receptor type BHomo sapiens (human)
renin secretion into blood streamEndothelin receptor type BHomo sapiens (human)
regulation of heart rateEndothelin receptor type BHomo sapiens (human)
regulation of pHEndothelin receptor type BHomo sapiens (human)
cell surface receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
negative regulation of adenylate cyclase activityEndothelin receptor type BHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin receptor type BHomo sapiens (human)
nervous system developmentEndothelin receptor type BHomo sapiens (human)
peripheral nervous system developmentEndothelin receptor type BHomo sapiens (human)
posterior midgut developmentEndothelin receptor type BHomo sapiens (human)
positive regulation of cell population proliferationEndothelin receptor type BHomo sapiens (human)
gene expressionEndothelin receptor type BHomo sapiens (human)
negative regulation of neuron maturationEndothelin receptor type BHomo sapiens (human)
response to organic cyclic compoundEndothelin receptor type BHomo sapiens (human)
vein smooth muscle contractionEndothelin receptor type BHomo sapiens (human)
calcium-mediated signalingEndothelin receptor type BHomo sapiens (human)
cGMP-mediated signalingEndothelin receptor type BHomo sapiens (human)
heparin metabolic processEndothelin receptor type BHomo sapiens (human)
melanocyte differentiationEndothelin receptor type BHomo sapiens (human)
regulation of fever generationEndothelin receptor type BHomo sapiens (human)
aldosterone metabolic processEndothelin receptor type BHomo sapiens (human)
enteric smooth muscle cell differentiationEndothelin receptor type BHomo sapiens (human)
positive regulation of urine volumeEndothelin receptor type BHomo sapiens (human)
renal sodium excretionEndothelin receptor type BHomo sapiens (human)
epithelial fluid transportEndothelin receptor type BHomo sapiens (human)
vasoconstrictionEndothelin receptor type BHomo sapiens (human)
vasodilationEndothelin receptor type BHomo sapiens (human)
negative regulation of apoptotic processEndothelin receptor type BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin receptor type BHomo sapiens (human)
macrophage chemotaxisEndothelin receptor type BHomo sapiens (human)
response to painEndothelin receptor type BHomo sapiens (human)
enteric nervous system developmentEndothelin receptor type BHomo sapiens (human)
regulation of epithelial cell proliferationEndothelin receptor type BHomo sapiens (human)
negative regulation of protein metabolic processEndothelin receptor type BHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin receptor type BHomo sapiens (human)
positive regulation of penile erectionEndothelin receptor type BHomo sapiens (human)
establishment of endothelial barrierEndothelin receptor type BHomo sapiens (human)
renal sodium ion absorptionEndothelin receptor type BHomo sapiens (human)
calcium ion transmembrane transportEndothelin receptor type BHomo sapiens (human)
cellular response to lipopolysaccharideEndothelin receptor type BHomo sapiens (human)
protein transmembrane transportEndothelin receptor type BHomo sapiens (human)
podocyte differentiationEndothelin receptor type BHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin receptor type BHomo sapiens (human)
renal albumin absorptionEndothelin receptor type BHomo sapiens (human)
neuroblast migrationEndothelin receptor type BHomo sapiens (human)
chordate pharynx developmentEndothelin receptor type BHomo sapiens (human)
response to sodium phosphateEndothelin receptor type BHomo sapiens (human)
response to endothelinEndothelin receptor type BHomo sapiens (human)
developmental pigmentationEndothelin receptor type BHomo sapiens (human)
mitotic cell cycleEndothelin-1 receptorHomo sapiens (human)
branching involved in blood vessel morphogenesisEndothelin-1 receptorHomo sapiens (human)
response to hypoxiaEndothelin-1 receptorHomo sapiens (human)
in utero embryonic developmentEndothelin-1 receptorHomo sapiens (human)
blood vessel remodelingEndothelin-1 receptorHomo sapiens (human)
response to amphetamineEndothelin-1 receptorHomo sapiens (human)
regulation of heart rateEndothelin-1 receptorHomo sapiens (human)
glomerular filtrationEndothelin-1 receptorHomo sapiens (human)
cardiac chamber formationEndothelin-1 receptorHomo sapiens (human)
left ventricular cardiac muscle tissue morphogenesisEndothelin-1 receptorHomo sapiens (human)
atrial cardiac muscle tissue developmentEndothelin-1 receptorHomo sapiens (human)
cardiac neural crest cell migration involved in outflow tract morphogenesisEndothelin-1 receptorHomo sapiens (human)
noradrenergic neuron differentiationEndothelin-1 receptorHomo sapiens (human)
intracellular calcium ion homeostasisEndothelin-1 receptorHomo sapiens (human)
smooth muscle contractionEndothelin-1 receptorHomo sapiens (human)
mitochondrion organizationEndothelin-1 receptorHomo sapiens (human)
signal transductionEndothelin-1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
activation of adenylate cyclase activityEndothelin-1 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEndothelin-1 receptorHomo sapiens (human)
respiratory gaseous exchange by respiratory systemEndothelin-1 receptorHomo sapiens (human)
regulation of blood pressureEndothelin-1 receptorHomo sapiens (human)
cell population proliferationEndothelin-1 receptorHomo sapiens (human)
response to woundingEndothelin-1 receptorHomo sapiens (human)
gene expressionEndothelin-1 receptorHomo sapiens (human)
protein kinase A signalingEndothelin-1 receptorHomo sapiens (human)
regulation of glucose transmembrane transportEndothelin-1 receptorHomo sapiens (human)
neural crest cell fate commitmentEndothelin-1 receptorHomo sapiens (human)
artery smooth muscle contractionEndothelin-1 receptorHomo sapiens (human)
neuron remodelingEndothelin-1 receptorHomo sapiens (human)
heparin metabolic processEndothelin-1 receptorHomo sapiens (human)
thyroid gland developmentEndothelin-1 receptorHomo sapiens (human)
cellular response to oxidative stressEndothelin-1 receptorHomo sapiens (human)
embryonic heart tube developmentEndothelin-1 receptorHomo sapiens (human)
aorta developmentEndothelin-1 receptorHomo sapiens (human)
vasoconstrictionEndothelin-1 receptorHomo sapiens (human)
norepinephrine metabolic processEndothelin-1 receptorHomo sapiens (human)
middle ear morphogenesisEndothelin-1 receptorHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionEndothelin-1 receptorHomo sapiens (human)
cellular response to human chorionic gonadotropin stimulusEndothelin-1 receptorHomo sapiens (human)
enteric nervous system developmentEndothelin-1 receptorHomo sapiens (human)
sympathetic nervous system developmentEndothelin-1 receptorHomo sapiens (human)
axon extensionEndothelin-1 receptorHomo sapiens (human)
embryonic skeletal system developmentEndothelin-1 receptorHomo sapiens (human)
neuromuscular processEndothelin-1 receptorHomo sapiens (human)
sodium ion homeostasisEndothelin-1 receptorHomo sapiens (human)
canonical Wnt signaling pathwayEndothelin-1 receptorHomo sapiens (human)
face developmentEndothelin-1 receptorHomo sapiens (human)
axonogenesis involved in innervationEndothelin-1 receptorHomo sapiens (human)
establishment of endothelial barrierEndothelin-1 receptorHomo sapiens (human)
pharyngeal arch artery morphogenesisEndothelin-1 receptorHomo sapiens (human)
renal sodium ion absorptionEndothelin-1 receptorHomo sapiens (human)
calcium ion transmembrane transportEndothelin-1 receptorHomo sapiens (human)
cellular response to follicle-stimulating hormone stimulusEndothelin-1 receptorHomo sapiens (human)
cellular response to luteinizing hormone stimulusEndothelin-1 receptorHomo sapiens (human)
protein transmembrane transportEndothelin-1 receptorHomo sapiens (human)
glomerular endothelium developmentEndothelin-1 receptorHomo sapiens (human)
podocyte differentiationEndothelin-1 receptorHomo sapiens (human)
endothelin receptor signaling pathway involved in heart processEndothelin-1 receptorHomo sapiens (human)
renal albumin absorptionEndothelin-1 receptorHomo sapiens (human)
vascular associated smooth muscle cell developmentEndothelin-1 receptorHomo sapiens (human)
mesenchymal cell apoptotic processEndothelin-1 receptorHomo sapiens (human)
sympathetic neuron axon guidanceEndothelin-1 receptorHomo sapiens (human)
semaphorin-plexin signaling pathway involved in axon guidanceEndothelin-1 receptorHomo sapiens (human)
podocyte apoptotic processEndothelin-1 receptorHomo sapiens (human)
meiotic cell cycle process involved in oocyte maturationEndothelin-1 receptorHomo sapiens (human)
cranial skeletal system developmentEndothelin-1 receptorHomo sapiens (human)
response to acetylcholineEndothelin-1 receptorHomo sapiens (human)
regulation of protein localization to cell leading edgeEndothelin-1 receptorHomo sapiens (human)
positive regulation of cation channel activityEndothelin-1 receptorHomo sapiens (human)
endothelin receptor signaling pathwayEndothelin-1 receptorHomo sapiens (human)
developmental pigmentationEndothelin-1 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
endothelin receptor activityEndothelin receptor type BHomo sapiens (human)
protein bindingEndothelin receptor type BHomo sapiens (human)
peptide hormone bindingEndothelin receptor type BHomo sapiens (human)
type 1 angiotensin receptor bindingEndothelin receptor type BHomo sapiens (human)
phosphatidylinositol phospholipase C activityEndothelin-1 receptorHomo sapiens (human)
endothelin receptor activityEndothelin-1 receptorHomo sapiens (human)
protein bindingEndothelin-1 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneEndothelin receptor type BHomo sapiens (human)
nuclear membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneEndothelin receptor type BHomo sapiens (human)
plasma membraneEndothelin-1 receptorHomo sapiens (human)
plasma membraneEndothelin-1 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID15842Aqueous solubility in pH 7.4 phosphate buffer1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Butenolide endothelin antagonists with improved aqueous solubility.
AID574640Biodistribution on BALB/c mouse bile at 2.5 nmol/kg, iv after 30 mins in presence of PD1567072011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Development and evaluation of endothelin-A receptor (radio)ligands for positron emission tomography.
AID14097Maximum observed concentration in oral (5 mg/kg) fed dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66034Inhibition of Endothelin A receptor mediated (ET-1) release of arachidonic acid from rabbit renal artery vascular smooth muscle cells1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID234515Selectivity of compound on ET B with respect to ET A receptor1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66520Inhibition of [125I]ET1 binding to recombinant human Endothelin B receptor.1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Butenolide endothelin antagonists with improved aqueous solubility.
AID452800Displacement of [125I]ET1 from endothelin B receptor in DBA mouse microsomes2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
PET-compatible endothelin receptor radioligands: synthesis and first in vitro and in vivo studies.
AID68315Inhibition of [125I]-ET-1 binding to recombinant human Endothelin A receptor.1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Butenolide endothelin antagonists with improved aqueous solubility.
AID452801Selectivity index, ratio of Ki for DBA mouse microsome endothelin B receptor to Ki for DBA mouse microsome endothelin A receptor2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
PET-compatible endothelin receptor radioligands: synthesis and first in vitro and in vivo studies.
AID68338Antagonistic activity against human Endothelin A receptor expressed in LtK1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.
AID10718Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID166795In vitro inhibition of ET-1 induced contraction of rabbit femoral artery rings.1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Butenolide endothelin antagonists with improved aqueous solubility.
AID574642Biodistribution on BALB/c mouse urine assessed as uptake index at 2.5 nmol/kg, iv after 30 mins in presence of PD1567072011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Development and evaluation of endothelin-A receptor (radio)ligands for positron emission tomography.
AID66367Binding affinity against human cloned Endothelin B receptor expressed in CHO-K1 cells1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66202Inhibition of [125I]ET1 binding to rat aorta membrane Endothelin A receptor1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.
AID68301Binding affinity against human cloned endothelin A receptor expressed in LTK-cells1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID20779Time to reach maximum observed concentration in oral (5 mg/kg) fasted dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID574639Biodistribution on BALB/c mouse duodenum at 2.5 nmol/kg, iv after 30 mins in presence of PD1567072011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Development and evaluation of endothelin-A receptor (radio)ligands for positron emission tomography.
AID68488Inhibitory activity against human Endothelin A receptor in chinese hamster ovary cells1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
AID66545Tested for antagonistic activity against Endothelin B receptor in the humans (CHO expressed).1995Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8
Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists.
AID23580Mean of apparent terminal phase elimination half-life in oral (5 mg/kg) fasted dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66529Inhibition of Endothelin B receptor mediated (ET-3) release of arachidonic acid from human cloned receptors / CHO-K1 cells1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66709Inhibition of [125I]ET1 binding to porcine kidney inner medulla membrane Endothelin B receptor1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Endothelin antagonists: evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster.
AID23581Mean of apparent terminal phase elimination half-life in oral (5 mg/kg) fed dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66048Antagonism of ET-1 induced contraction of rabbit femoral artery rings (Endothelin A receptor mediated)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID66691Inhibitory activity against human Endothelin B receptor in chinese hamster ovary cells1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
2,4-Diarylpyrrolidine-3-carboxylic acids--potent ETA selective endothelin receptor antagonists. 1. Discovery of A-127722.
AID574638Biodistribution on BALB/c mouse stomach at 2.5 nmol/kg, iv after 30 mins in presence of PD1567072011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Development and evaluation of endothelin-A receptor (radio)ligands for positron emission tomography.
AID10717Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID10716Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID20780Time to reach maximum observed concentration in oral (5 mg/kg) fed dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID23579Mean of apparent terminal phase elimination half-life after intravenous administration of 2.5 mg/kg in dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID17945Absolute oral bioavailability in oral (5 mg/kg) fed dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID17944Absolute oral bioavailability in oral (5 mg/kg) fasted dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID574641Biodistribution on BALB/c mouse urine at 2.5 nmol/kg, iv after 30 mins in presence of PD1567072011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
Development and evaluation of endothelin-A receptor (radio)ligands for positron emission tomography.
AID176677Compound was evaluated for acute hypoxic pulmonary hypertension in rats1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Butenolide endothelin antagonists with improved aqueous solubility.
AID14096Maximum observed concentration in oral (5 mg/kg) fasted dogs1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID452799Displacement of [125I]ET1 from endothelin A receptor in DBA mouse microsomes2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
PET-compatible endothelin receptor radioligands: synthesis and first in vitro and in vivo studies.
AID66043Inhibition of ET-1 induced contraction of rabbit femoral artery rings (Endothelin A receptor mediated)1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
AID493017Wombat Data for BeliefDocking1997Journal of medicinal chemistry, Mar-28, Volume: 40, Issue:7
Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (71.43)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.28 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]